Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 3/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1470338 | 0.80 | CYP4F2 (0.36) | — | |
| SCHEMBL1467530 | 0.80 | CYP4F2 (0.36) | — | |
| SCHEMBL1468666 | 0.80 | CYP4F2 (0.36) | — | |
| SCHEMBL1835149 | 0.80 | — | — | |
| SCHEMBL26492623 | 0.80 | — | — | |
| SCHEMBL1834809 | 0.78 | CYP1A2 (0.36) | CYP2C19LMNAALDH1A1 | |
| SCHEMBL605108 | 0.78 | CYP2C19 (0.34) | CYP2C19LMNAALDH1A1 | |
| SCHEMBL12141039 | 0.76 | — | — | |
| SCHEMBL245571 | 0.76 | — | — | |
| SCHEMBL30716833 | 0.76 | CYP2C19 (0.42) | CYP2C19TDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8563742-B2 | Substituted aminothiazole derivatives, pharmaceutical compositions, and methods of use | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-10-22 | — | — | US | disclosed |
| US-20120264790-A1 | ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2012-10-18 | — | — | US | disclosed |
| EP-2320738-A1 | SUBSTITUTED AMINOTHIAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE | TransTech Pharma, Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| US-20100056587-A1 | Substituted Aminothiazole Derivatives, Pharmaceutical Compositions, And Methods Of Use | VTVX HOLDINGS I LLC | 2010-03-04 | — | — | US | disclosed |
| WO-2010025142-A1 | SUBSTITUTED AMINOTHIAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE | TRANSTECH PHARMA, INC. (US) | 2010-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264790-A1 | ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | LPAR2, LIPG, EDF1 | OPRL1 2189/4885CYP2C19 2273/4885OPRM1 3447/4885 |
| US-20100056587-A1 | Substituted Aminothiazole Derivatives, Pharmaceutical Compositions, And Methods Of Use | MC4R, MC3R, MC5R | OPRL1 54/4885CYP2C19 1351/4885OPRM1 282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.